Last reviewed · How we verify

Myotonic disorder — Treatment Landscape & Competitive Intelligence

Myotonic disorder (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myotonic disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Mexitil MEXILETINE Boehringer Ingelheim Antiarrhythmic 5-hydroxytryptamine receptor 2B 1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Boehringer Ingelheim · 1 drug in Myotonic disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myotonic disorder:

Cite this brief

Drug Landscape (2026). Myotonic disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myotonic-disorder. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing